This symposium is designed for medical oncologists, clinical and industry researchers, and young oncologists.
- To provide an introduction on preclinical data and molecular genetics relevant for the understanding of functional mechanisms in the MAPK pathway.
- To understand the regulation of MAPK signalling, interaction with other pathways and basic concepts of translating preclinical observations into cancer clinics.
- To understand the rationale and different approaches to inhibiting the MAPK pathway.
- To provide an essential update on different aspects important for rational clinical development of the RAS/ERK/MEK inhibitors.
- To provide an update on biomarkers research, mechanisms of developing resistance to RAS/ERK/MEK inhibitors and critically discuss how to overcome drug resistance.
- To explore from a clinical perspective recent achievements and data from ongoing clinical trials targeting all axes of the RAS/ERK/MEK pathway across a range of solid tumours.
The Symposium programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. Find out more about ESMO-MORA accreditation.
The Symposium programme will be submitted for accreditation to the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Find out how to convert EACCME credit to AMA credit.